Method for analyzing host proteins in recombinant protein preparations
Patent Information
- Application Number
- KR1020267029026
- Authority / Receiving Office
- KR · KR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-06
- Filing Date
- 2025-03-04
- Publication Date
- 2026-11-10
AI Technical Summary
Current methods for detecting and removing host cell proteins (HCPs) in biopharmaceuticals, such as monoclonal antibodies, are inconsistent and time-consuming, leading to variability in HCP identification and posing risks to patient safety and drug efficacy due to the high dynamic range of HCPs and the lack of a standardized, rapid sample preparation method.
A novel sample preparation method using Fc receptor (FcγRIIIa) affinity chromatography followed by acetone precipitation and digestion in sodium deoxycholate and N-dodecyl-beta-D-maltoside, allowing for efficient isolation and digestion of HCPs in a single-tube process, reducing variability and processing time.
This method significantly improves HCP identification and quantification, enhancing the reliability of HCP removal strategies and supporting high-throughput analysis, thereby improving the safety and efficacy of biopharmaceuticals.
Smart Images

Figure PCT00006_ABST
Abstract
Description
Technology Field
[0001] The present invention relates to an improved sample preparation method for LC-MS / MS analysis that enables the efficient isolation, purification, and identification of protein contaminants, such as host cell proteins (HCP), as process-related impurities generated during the manufacture of biopharmaceuticals such as monoclonal antibodies (mAbs). Background Technology
[0002] Host cell proteins (HCPs) are process-related impurities generated during the manufacturing of biopharmaceuticals and can contaminate the final product if not efficiently removed. Due to their potential impact on product safety and efficacy, regulatory authorities require that HCPs be removed from the final manufactured biopharmaceuticals to trace levels. The current standard method for detecting HCPs is the enzyme-linked immunosorbent assay (ELISA), which indicates only the total amount of HCPs.
[0003] Sensitive, high-throughput LC-MS technology, which enables the identification and quantification of individual HCPs, has proven to be a potential alternative technology. However, differences in sample preparation methods and MS acquisition techniques have resulted in discrepancies in the HCPs detected in numerous studies, which can compromise patient safety and efficacy. To address this issue, the inventors have developed a novel and reproducible method for the isolation and digestion of HCPs for subsequent mass spectrometry detection, applicable to downstream processes of recombinant proteins such as monoclonal antibodies (mAbs) and easily performed in a standard laboratory instead of requiring dedicated instruments.
[0004] Therapeutic monoclonal antibodies (mAbs) are currently the main class of newly approved drugs worldwide, with over 100 mAbs approved for the treatment of various diseases and approximately 1,200 currently in clinical trials.
[0005] Most mAbs are produced in engineered cell lines, particularly mammalian cells, which can introduce unwanted process-related impurities known as host cell proteins (HCPs). If these HCPs are not effectively removed, they can induce immunogenic responses in patients and compromise product stability by degrading formulation excipients (e.g., polysorbates) or the mAbs themselves. Consequently, regulatory authorities such as the European Medicines Evaluation Agency (EMEA) and the Food and Drug Administration (FDA) have mandated that HCPs be extensively removed throughout the manufacturing process. Despite the absence of prescribed specifications, manufacturers typically aim for HCP levels in the final product ranging from 1 to 100 parts per million (ppm). Therefore, various analytical techniques have been developed to routinely assess ppm levels of HCP during the manufacturing of biopharmaceuticals.
[0006] Enzyme-linked immunosorbent assays (ELISA) have traditionally been used to monitor ppm levels of HCP. However, because ELISA cannot identify individual HCPs, most biopharmaceutical manufacturers employ orthogonal methods for risk mitigation. Due to recent advancements in liquid chromatography-mass spectrometry (LC-MS), bottom-up proteomics has the potential to become a promising tool for HCP evaluation. In this method, proteins are enzymatically digested and identified at the peptide level. Once HCPs are identified, specific removal procedures and risk assessments can be performed to support process development. However, given the high dynamic range (orders 5 to 6) associated with the relative amount of mAbs to HCPs in samples from any mAb manufacturing process, the success of this strategy depends heavily on the sample preparation procedure (e.g., peptide fractionation or mAb depletion) and MS detection sensitivity. An improved sample preparation approach is needed to address this challenge and lower the detection limit of HCP.
[0007] Due to differences in the workflows used, discrepancies in HCPs identified in numerous studies can pose risks to patient safety and drug efficacy. For example, the number of HCPs identified from NIST mAbs in various studies ranged from 60 to 850 proteins. The diversity of HCPs identified in therapeutic drugs is even more critical when this data is used to guide manufacturing processes and assess the safety of final drugs intended for widespread community use.
[0008] One of the major sources of variability in HCP identification by bottom-up proteomics is sample preparation, which varies by manufacturer and biopharmaceutical product. Various methods have been used to fractionate peptides or deplete mAbs. Recently, native digestion and molecular weight cut-off filtration have been used as alternatives. However, these techniques are not standardized and may only be applicable to specific subclasses of mAbs, making them less suitable for quantifying problematic HCPs. For example, previous studies have shown that phospholipase B-like 2 (PLBL2) and cathepsin D interact with mAbs under protein A chromatography conditions and appear at higher levels in the eluent. These HCPs have the potential to induce immunogenicity or hydrolyze mAbs. Therefore, performing LC-MS / MS analysis after using protein A chromatography to isolate HCPs may not provide a complete picture of HCPs with specific risk levels for use in root cause investigation. Significant progress has been made in overcoming this problem by using pre-elution washes to disrupt HCP-mAb interactions and improve HCP removal by Protein A chromatography. However, studies indicate that the types of HCP co-eluted with the product vary by molecule and pose a significant bottleneck in the biopharmaceutical industry, particularly when short processing times are essential.
[0009] Furthermore, the time-consuming sample preparation processes required for HCP, including reduction, alkylation, desalination, and overnight digestion, can hinder high-throughput LC-MS analysis. Therefore, when time and sample throughput are critical constraints, the lack of a rapid and universal method for HCP isolation and digestion remains a major obstacle.
[0010] To address these challenges, the present application provides an integrated strategy aimed at ensuring efficient and reliable sample preparation (isolation and digestion) of protein contaminants across different classes of recombinant proteins. This approach aims to reduce the dynamic range of recombinant proteins versus protein contaminants and provides a reproducible, simple, and easily implementable method that can be performed in a standard laboratory. This approach was applied to investigate the identification and quantification of high-risk HCPs in a case study on an mAb bioprocess.
[0011] Recently, Fc receptor (FcγRIIIa) affinity chromatography has been used to improve the analytical characterization of mAbs by monitoring Fc glycan heterogeneity during process development and manufacturing [1, 2]. In the present invention, an Fc receptor (FcγRIIIa) affinity column was used to deplete mAbs and isolate the concentrated HCP fraction. Subsequently, the fraction was concentrated using a blocking filter and the protein was precipitated with acetone. Then, the protein pellet was solubilized, denatured, reduced, and digested in a solution containing sodium deoxycholate (SDC) and N-dodecyl-beta-D-maltoside (DDM) as suitable detergents. Comparison of HCP fractions isolated by FcγRIIIa and Protein A chromatography revealed that HCP identification was significantly improved when using FcγRIIIa. The newly developed method simplifies the sample preparation process, reducing variability and processing time. This advancement provides valuable information regarding problematic or high-risk HCPs, offering the potential to enhance control strategies during purification process evaluations for biopharmaceutical companies.
[0012] To reduce the variability in protein contaminant identification caused by different sample preparation procedures and low protein contaminant concentrations, a more efficient sample preparation workflow is required. This application discloses a novel procedure combining protein contaminant isolation in an Fc receptor affinity column with “single-tube” protein digestion. This method has been shown to significantly increase the number of protein contaminants identified compared to protein A chromatography by reducing the ratio of recombinant protein to protein contaminant amounts. This approach is applicable to a wide range of recombinant proteins and provides a reproducible, simple, and easily implementable method that can be performed in a standard laboratory. The disclosed sample preparation method will be useful for monitoring protein contaminant levels during the manufacturing process and can be widely used for root cause investigations. Furthermore, it can assist in evaluating the bio-similarity of candidate substances to reference products and guide process development to improve overall HCP removal in downstream processes.
[0013] The present application provides a rapid and efficient workflow for the isolation and digestion of protein contaminants such as HCP. Fc receptor (FcγRIIIa) affinity chromatography was used to separate HCP fractions by mAb depletion. HCP within the HCP fraction can be precipitated and digested using a “single-tube” method that improves digestion performance and prevents sample loss of problematic low-content protein contaminants. The method of the present invention was shown to be superior to protein A affinity chromatography for monitoring problematic HCP.
[0014] In one aspect, the present invention relates to a method for isolating and analyzing one or more protein contaminants from a sample comprising a recombinant protein and one or more protein contaminants, the method comprising: (a) a fractionation step of a sample comprising a recombinant protein and one or more protein contaminants, wherein the fractionation comprises contacting the sample with an Fc receptor affinity resin and collecting a flow-through (FT) to obtain a fraction comprising one or more protein contaminants; and (b) an analysis step of one or more protein contaminants in the fraction comprising one or more protein contaminants. Brief explanation of the drawing
[0015] Fig. 1: Experimental workflow. mAb is depleted using an Fc receptor column (e.g., FcγRIIIa), and the collected HCP fraction is concentrated (e.g., by a 10 kDa molecular weight cutoff filter). The protein is precipitated (e.g., by the addition of acetone), lysed (e.g., in an SDC / DDM solution), reduced, and digested (e.g., by trypsin). The peptide is analyzed by LC-MS / MS, and the raw file is searched against the CHO protein sequence database to identify the HCP. Fig. 2: FcγRIIIa of (A) mAb1 and (B) mAb2 in the glycosylated form (dotted line) and the form after removal of N-glycans with PNGase F (solid line). Affinity UV chromatogram (280 nm). Fig. 3: Analysis of the mAb2 fragment after digestion with FabALACTICA. (A) FcγRIIIa affinity chromatogram detected by UV at 280 nm (FT interval of this FcγRIIIa affinity column is approx. 5 min to approx. 12 min); (B) FT peak (Fraction 1) (RT interval of this RP-LC column is approx. 5 min to 20 min) and (C) RP-LC-MS analysis of the peak at RT 30 min to 45 min (Fraction 2); (D) unwound mass spectra of Fraction 1 and (E) Fraction 2. Fig. 4: Analysis of the mAb2 fragment after digestion with IdeS. (A) FcγRIIIa chromatogram detected by UV at 280 nm (FT interval of this FcγRIIIa affinity column is approx. 5 min to approx. 12 min); (B) RP-LC-MS analysis of the FT fraction (RT interval of this RP-LC column is approx. 5 min to 20 min); unwound mass spectra of peaks with RTs of (C) 14.8 min and (D) 16.8 min. Fig. 5: UPS1 protein identification and peptide intensity of all detected peptides after digestion at 37°C for 15 to 60 minutes. The numbers above the bars represent the average sequence coverage of all identified UPS1 proteins. The sequence coverage levels for the identified UPS1 proteins are indicated by different colors. Fig. 6: Overlapping UV chromatogram (280 nm) for subsequent three injections of mAb1 obtained by FcγRIIIa affinity chromatography. Fraction 1 was collected and used in a bottom-up approach for HCP confirmation. Fig. 7: Distribution of signal intensity (MS signal) of all detected peptides of protein PLBL2 in each fraction of (A) protein A and (B) FcγRIIIa affinity chromatography. Fig. 8: Schematic diagram of the Protein A workflow according to [3]. Briefly, the workflow comprises the following steps: (I) Equilibrate the Protein A column (HiTrap MabSelect SuRe, 1 mL, Sigma-Aldrich) with 10 mL of 20 mM Na2HPO4 (pH 7.3). (II) Dilute 5 mg of mAb1 to a final volume of 2 mL (concentration 5 mg / mL) using 20 mM Na2HPO4 (pH 7.3), load it onto the Protein A column, and collect the pass-through (F1-Protein A). (III) Load the pre-elution solution onto the column and collect the fraction (F2-Protein A). (IV) Re-equilibrate the column with 20 mM Na2HPO4, pH 7.3 (discard). (V) elute mAb1 with 5.0 mL of 100 mM glycine buffer (pH 2.8) and collect the fraction (F3-protein A). Specific details for implementing the invention
[0016] List of abbreviations used in this application
[0017] ABC ammonium bicarbonate
[0018] ACN Acetonitrile
[0019] ADCC Antibody-dependent cell-mediated cytotoxicity
[0020] AGC Automatic gain control
[0021] CHAPS 3-[(3-colamidopropyl)dimethylammonio]-1-propanesulfonate
[0022] DDM N-dodecyl-beta-D-maltoside
[0023] DTT dithiothreitol
[0024] ELISA Enzyme-linked immunosorbent analysis
[0025] EMEA European Medicines Agency
[0026] FDA Food and Drug Administration
[0027] FDR False Discovery Rate
[0028] FT Passing
[0029] HC Heavy chain
[0030] HCD High-energy C-trap dissociation
[0031] HCP(s) Host cell protein(s)
[0032] LC Light chain
[0033] LC-MS / MS Liquid Chromatography-(Tandem) Mass Spectrometry
[0034] mAb Monoclonal antibodies
[0035] MS Mass spectrometry
[0036] MS / MS Tandem mass spectrometry
[0037] MW molecular weight
[0038] NIST National Institute of Standards and Technology
[0039] ppm parts per million
[0040] RP Inverse image
[0041] RT Time of stay
[0042] SDC sodium deoxycholate
[0043] SDS sodium dodecyl sulfate
[0044] THPP Tris(3-hydroxypropyl)phosphine
[0045] TCEP Tris 2-Carboxyethylphosphine
[0046] TFA trifluoroacetic acid
[0047] TIC Total ion current
[0048] UHPLC Ultra-high performance liquid chromatography
[0049] UPS-1 Universal Proteomics Standard Material 1
[0050] Fractionating a sample containing recombinant protein and one or more protein contaminants depletes the recombinant protein from the sample and thereby relatively concentrates one or more protein contaminants, serving to support efficient and sensitive detection and analysis, for example, by mass spectrometry.
[0051] As described herein, when a sample is brought into contact with an Fc receptor affinity resin, two fractions are generated: a binding fraction and a pass-through fraction. The binding fraction, which may also be referred to as the retention fraction, comprises all proteins contained in the sample that interact with the affinity resin used, that is, all proteins that are retained by the Fc receptor affinity resin and thus eluted from the affinity resin significantly later than the pass-through fraction. The pass-through fraction comprises all proteins contained in the sample that do not interact with or do not interact with the affinity resin used. As referred to herein, “collecting the pass-through fraction” means collecting the eluent or at least a portion of the eluent from the Fc receptor affinity resin under eluent conditions in which the recombinant protein binds to the affinity resin. Accordingly, “collecting the pass-through fraction” may refer to collecting the eluent or at least a portion of the eluent discharged from the chromatography column under eluent conditions in which the recombinant protein binds to the affinity resin contained in the column. The eluent thus collected may also be referred to as the collected pass-through. This contains at least some, preferably all, of the protein that is not bound to (and is not retained by) the Fc receptor affinity resin. For readability, the term pass-through is used throughout the specification, but it should be understood to encompass not only the pass-through of the chromatography column, but also any solution obtained after contacting the sample with the Fc receptor affinity resin and containing at least some, preferably all, of the protein that is not bound to the Fc receptor affinity resin.
[0052] In a preferred embodiment, the one or more protein contaminants are one or more host cell proteins. The host cell proteins are protein contaminants derived from the host cells used to produce the recombinant protein. The recombinant protein is typically produced in cell cultures using CHO, NS0, Sp2 / 0, HEK293, or PER.C6 cells. Accordingly, in a specific embodiment, the one or more protein contaminants are host cell proteins derived from cell lines selected from the group consisting of CHO, NS0, Sp2 / 0, HEK293, and PER.C6 cells. In a preferred embodiment, the one or more protein contaminants are host cell proteins derived from the CHO cell line.
[0053] A method according to the present invention comprises fractionating a sample comprising a recombinant protein and one or more protein contaminants, wherein the fractionation comprises the step of contacting the sample with an Fc receptor affinity resin and collecting the pass-through to obtain a fraction comprising one or more protein contaminants. In some embodiments, the Fc receptor affinity resin comprises an immobilized Fc receptor that binds to the recombinant protein. This means that the Fc receptor immobilized on the Fc receptor affinity resin is selected to bind to the recombinant protein. When a specific interaction occurs between the Fc receptor and the recombinant protein, the Fc receptor “binds” to the recombinant protein in the sense of this application. This causes the recombinant protein to associate with the Fc receptor affinity resin and reduces the amount of recombinant protein in the pass-through compared to the amount of recombinant protein in the initial sample (before fractionation).
[0054] In one embodiment, the Fc receptor affinity resin is a resin to which an Fc receptor is attached, preferably covalently bonded. The Fc receptor is immobilized on the resin. The resin may be any known resin that is stable under conditions typically applied to protein affinity purification (e.g., affinity chromatography), and a widely used example is polymethacrylate. In a preferred embodiment, the resin is used in the form of non-porous or porous polymethacrylate-based beads. The typical particle size of the beads is about 2 to 15 micrometers, e.g., 5 or 10 micrometers. For porous resins, the typical nominal pore size may be about 100 nm. Thus, the Fc receptor affinity resin is a resin in which the Fc receptor is immobilized on the stationary phase, and is typically used in the form of a chromatography column packed with a resin having immobilized Fc receptors.
[0055] In one embodiment, the Fc receptor affinity resin is an Fc gamma receptor affinity resin or a neonatal Fc receptor (FcRn) affinity resin, preferably an Fc gamma receptor affinity resin. The Fc gamma receptor affinity resin may be a type I Fc gamma receptor (FcγR) affinity resin, a type II Fc gamma receptor (FcγR) affinity resin, or a type III Fc gamma receptor (FcγR) affinity resin; preferably, the Fc gamma receptor affinity resin is a type I Fc gamma receptor (FcγR) affinity resin; more preferably, the type I Fc gamma receptor (FcγR) affinity resin is selected from the group of FcγRI, FcγRIIa, FcγRIIb, FcγRIIc, FcγRIIIa, and FcγRIIIb affinity resins; Much more preferably, the type I Fc gamma receptor (FcγR) affinity resin is an FcγRIIIa affinity resin. Thus, in a preferred embodiment, the Fc receptor affinity resin is a type I Fc gamma receptor (FcγR) affinity resin. In a further preferred embodiment, the type I Fc gamma receptor (FcγR) affinity resin is selected from the group of FcγRI, FcγRIIa, FcγRIIb, FcγRIIc, FcγRIIIa, and FcγRIIIb affinity resins. In a more preferred embodiment, the type I Fc gamma receptor (FcγR) affinity resin is an FcγRIIIa affinity resin.
[0056] Fc receptor affinity resins can be used in the form of chromatography columns. Fc receptor affinity resins in the form of chromatography columns are used in column chromatography. Accordingly, in one embodiment, the fractionation comprises the step of contacting a sample with an Fc receptor affinity resin, said contact comprises column chromatography.
[0057] Affinity chromatography generally involves the use of a stationary phase (e.g., an Fc receptor affinity resin) and a mobile phase. In the context of the present invention, the mobile phase used in Fc receptor affinity chromatography may be any mobile phase suitable for use with the stationary phase used (i.e., the Fc receptor affinity chromatography column used). Chakrabarti et al.
[12] disclose conditions suitable for protein purification using Fc receptor affinity chromatography.
[0058] In some embodiments, column chromatography using an Fc receptor affinity resin as described herein comprises the use of a mobile phase which is an aqueous buffer having a pH of about 3 to about 8, preferably about 4 to about 8, more preferably about 4.5 to about 7.5. In some embodiments, column chromatography comprises the use of a mobile phase which is a citrate buffer (e.g., ammonium citrate) or an acetate buffer (e.g., ammonium acetate). In some embodiments, column chromatography comprises the use of a mobile phase which is an aqueous buffer having a buffer concentration of about 10 mM to about 200 mM, preferably about 20 mM to about 150 mM, more preferably about 30 mM to about 100 mM. In certain embodiments, the buffer concentration is about 50 mM.
[0059] In some embodiments, column chromatography involves the use of a mobile phase that is a gradient of two aqueous buffers. Typically, elution from the Fc acceptor affinity resin is achieved by gradually decreasing the pH of the mobile phase, for example, by using a pH gradient such as from about pH 7 to about pH 4, preferably from about pH 7.0 to about pH 4.0. Thus, in some embodiments, the mobile phase is a gradient of two aqueous buffers, the first buffer has a pH of about 6 to about 7, preferably about 6.0 to about 7.0, and the second buffer has a pH of about 3.5 to about 5, preferably about 4 to about 5, more preferably about 4.0 to about 5.0. In a preferred embodiment, the mobile phase is a gradient of two aqueous buffers, the first buffer has a pH of about 6.5 and the second buffer has a pH of about 4.5. In a specific embodiment, the mobile phase is a gradient of two aqueous citrate buffers with buffer concentrations of about 10 mM to about 200 mM, the first buffer has a pH of about 6 to about 7, preferably about 6.0 to about 7.0, and the second buffer has a pH of about 3.5 to about 5, preferably about 4 to about 5, more preferably about 4.0 to about 5.0.
[0060] As used herein, the term “recombinant protein” preferably refers to a protein produced recombinantly by a cell line. Recombinant proteins may be useful for therapeutic purposes. Thus, recombinant proteins may be therapeutic proteins. However, the usefulness of the disclosed method is not limited to recombinant proteins having therapeutic activity, but applies to any protein produced recombinantly.
[0061] The method according to the present invention relies on the fact that a recombinant protein is retained by an Fc receptor affinity resin, while one or more protein contaminants are not retained by the Fc receptor affinity resin. Accordingly, in some embodiments, the recombinant protein binds to the Fc receptor affinity resin. When a specific interaction occurs between the Fc receptor and the recombinant protein, the recombinant protein “binds” to the Fc receptor affinity resin in the sense of this application. This causes the recombinant protein to associate with the Fc receptor affinity resin and reduces the amount of recombinant protein in the pass-through compared to the amount of recombinant protein in the sample containing the recombinant protein and one or more protein contaminants prior to fractionation.
[0062] In some embodiments, the recombinant protein is an antibody or its antigen-binding fragment or an Fc fusion protein. In a preferred embodiment, the recombinant protein is an antibody or its antigen-binding fragment. The Fc fusion protein is a protein comprising an Fc domain recombinantly linked to the peptide or protein of interest. The Fc domain of the Fc fusion protein may be derived from, for example, an IgG-type constant region as described herein.
[0063] Accordingly, in one embodiment, the Fc domain is an IgG-type Fc domain. In a preferred embodiment, the Fc domain is an IgG1-type, IgG2-type, IgG3-type, or IgG4-type Fc domain. In a more preferred embodiment, the Fc domain is an IgG1-type, IgG2-type, or IgG4-type Fc domain. In an even more preferred embodiment, the Fc domain is an IgG1-type or IgG4-type Fc domain.
[0064] In some embodiments, the antibody or its antigen-binding fragment is a monoclonal antibody or its antigen-binding fragment. In some embodiments, the antibody or its antigen-binding fragment is a chimeric antibody or its antigen-binding fragment. In some embodiments, the antibody or its antigen-binding fragment is a humanized antibody or its antigen-binding fragment. In some embodiments, the antibody or its antigen-binding fragment is a human antibody or its antigen-binding fragment. In some embodiments, the antibody or its antigen-binding fragment is a single-strand antibody or its antigen-binding fragment. In some embodiments, the antibody or its antigen-binding fragment is a single-strand antibody or its antigen-binding fragment.
[0065] As used herein, the term monoclonal antibody refers to an antibody obtained from a substantially homogeneous population of antibodies, that is, the individual antibodies constituting said population are identical except for possible naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation) that may be present in small amounts.
[0066] The term human antibody includes antibodies having a variable region and an invariant region that substantially correspond to a human germline immunoglobulin sequence known in the art, including those described, for example, by Kabat et al. [6]. The human antibody of the present invention may include, for example, in the CDR, particularly in CDR3, an amino acid residue that is not encoded by the human germline immunoglobulin sequence (e.g., a mutation introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). The human antibody may have at least one, two, three, four, five, or more positions substituted with an amino acid residue that is not encoded by the human germline immunoglobulin sequence.
[0067] Additionally, as used herein, the term antibody also relates to derivatives or variants of the antibodies described herein that exhibit the same specificity as the antibodies described herein. Examples of antibody variants include humanized variants of non-human antibodies, affinity-mature antibodies (see, e.g., Hawkins et al. [7] and Lowman et al. [8]), and antibody mutants having altered effector function(s) (e.g., Kontermann and D Includes bel [9] (see reference).
[0068] In addition to full-length antibodies, the term antibody as used herein also includes antibody fragments and antibody derivatives such as scFv-Fc, hcIgG, or IgNAR antibodies. Additionally, (bispecific) single-strand antibodies, “Fc DART” antibodies and “IgG DART” antibodies, Triomab antibodies, CrossMab antibodies, otho-Fab IgG antibodies and DVD-IgG are considered (Kontermann 2015
[10] ).
[0069] In some embodiments, the recombinant protein comprises an Fc domain or a fragment of an Fc domain, preferably a glycosylated Fc domain or a fragment of a glycosylated Fc domain. In certain embodiments, the recombinant protein comprises an Fc domain or a fragment of an Fc domain and is an antibody or its antigen-binding fragment or an Fc fusion protein.
[0070] As used herein, the term Fc domain refers to a polypeptide comprising the variable domain(s) and the constant region of an antibody excluding the first constant region immunoglobulin domain. In the case of an IgG-type antibody, the Fc domain comprises immunoglobulin domains CH2 and CH3, and a hinge region between immunoglobulin domains CH2 and CH1.
[0071] In some embodiments, the Fc domain is a murine Fc domain or a human Fc domain. In a preferred embodiment, the Fc domain is a human Fc domain. In some embodiments, the Fc domain comprises immunoglobulin domains CH2 and CH3, and a hinge region between immunoglobulin domains CH2 and CH1, wherein the CH2 domain, CH3 domain and hinge region are of human origin.
[0072] In additional embodiments, the recombinant protein comprises an IgG-type constant region. In specific embodiments, the recombinant protein comprises an IgG-type constant region and is an antibody or its antigen-binding fragment or an Fc fusion protein.
[0073] As used herein, the IgG type constant region includes immunoglobulin domains CH1, CH2, and CH3, along with a hinge region between immunoglobulin domains CH2 and CH1. The IgG type constant region may be an IgG1 type, IgG2 type, IgG3 type, or IgG4 type constant region. Preferably, the IgG type constant region is an IgG1 type constant region, an IgG2 type constant region, or an IgG4 type constant region. More preferably, the IgG type constant region is an IgG1 type constant region or an IgG4 type constant region.
[0074] In some embodiments, the IgG type invariant region is a murine IgG type invariant region or a human IgG type invariant region. In a preferred embodiment, the IgG type invariant region is a human IgG type invariant region.
[0075] Accordingly, in some embodiments, the recombinant protein is an IgG-type antibody, preferably an IgG1-type antibody, an IgG2-type antibody, an IgG3-type antibody, or an IgG4-type antibody, more preferably an IgG1-type antibody, an IgG2-type antibody, or an IgG4-type antibody, and much more preferably an IgG1-type antibody or an IgG4-type antibody.
[0076] The interaction between the Fc receptor and its substrate may depend on the glycosylation profile of the substrate [1, 2, 12]. Therefore, the retention level achievable with an Fc receptor-based resin (e.g., an Fc receptor-based chromatography column) may depend on whether the recombinant protein substrate is glycosylated, particularly N-glycosylated. This applies particularly to embodiments where the recombinant protein is an antibody or its antigen-binding fragment or an Fc fusion protein, or to embodiments where the recombinant protein contains an Fc domain or an IgG-type constant region. For such recombinant proteins glycosylated within the Fc domain or the IgG-type constant region, retention in the Fc receptor-based resin is enhanced. As described in [1, 2], larger N-glycans generally increase the affinity of the Fc receptor for the recombinant protein substrate and thus extend the retention time in an Fc receptor affinity resin (e.g., an FcγRIIIa affinity resin). The number of terminal galactose sugar residues in N-glycans was also found to have a positive correlation with the retention time in Fc receptor affinity resins (e.g., FcγRIIIa affinity resins).
[0077] Accordingly, in certain embodiments, the recombinant protein (e.g., an antibody or its antigen-binding fragment or an Fc fusion protein) is glycosylated. In a preferred embodiment, the recombinant protein (e.g., an antibody or its antigen-binding fragment or an Fc fusion protein) contains an N-glycan, i.e., is N-glycosylated. In a further preferred embodiment, the recombinant protein contains an N-glycan at position 297 according to EU numbering or at the corresponding amino acid. In a specific preferred embodiment, the recombinant protein is an antibody or its antigen-binding fragment (e.g., an IgG-type antibody) or an Fc fusion protein, or contains an Fc domain or an IgG-type constant region, and contains an N-glycan at position 297 according to EU numbering (according to Edelman et al.
[11] ) or at the corresponding amino acid.
[0078] Glycans attached to asparagine residues are referred to herein as N-glycans. In the context of the present invention, the structure of N-glycans and the number of sugar residues contained therein may affect the retention of recombinant proteins by Fc receptor affinity resins (an exemplary overview thereof is provided in
[13] ). For example, N-glycans may contain core fucose sugars or may not contain core fucose sugars. N-glycans may also be oligosaccharides having 3 to 20, preferably 3 to 15, particularly 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 sugar residues.
[0079] In a specific embodiment, the recombinant protein comprises an Fc domain (e.g., an IgG-type Fc domain), and the Fc domain is glycosylated. In a preferred embodiment, the recombinant protein comprises an Fc domain (e.g., an IgG-type Fc domain), and the Fc domain comprises an N-glycan (i.e., is N-glycosylated). In a preferred embodiment, the recombinant protein comprises an Fc domain (e.g., an IgG-type Fc domain), and the Fc domain comprises an N-glycan at position 297 according to EU numbering. In some embodiments, the N-glycan included in the Fc domain is an oligosaccharide having 3 to 20, preferably 3 to 15, particularly 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 sugar residues.
[0080] In additional specific embodiments, the recombinant protein comprises an IgG-type constant region, and the IgG-type constant region is glycosylated. In a preferred embodiment, the recombinant protein comprises an IgG-type constant region, and the IgG-type constant region comprises an N-glycan. In a preferred embodiment, the recombinant protein comprises an IgG-type constant region, and the IgG-type constant region comprises an N-glycan at position 297 according to EU numbering. In some embodiments, the N-glycan within the IgG-type constant region is an oligosaccharide having 3 to 20, preferably 3 to 15, particularly 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 sugar residues.
[0081] Since antibody-dependent cell-mediated cytotoxicity (ADCC activity) requires interaction between an antibody (or its antigen-binding fragment) and an Fc receptor, in some embodiments, a recombinant protein (e.g., an antibody or its antigen-binding fragment) has ADCC activity. ADCC activity can be determined, for example, as described by Kiyoshi et al. [1].
[0082] A fraction containing one or more protein contaminants obtained after fractionation of a sample containing recombinant protein may be applied to the concentration of one or more protein contaminants. Accordingly, in one embodiment, the analysis of step b) includes the step of applying the fraction containing one or more protein contaminants to the concentration of one or more protein contaminants. In one embodiment, the concentration of one or more protein contaminants comprises (i.) the step of precipitating one or more protein contaminants; and (ii.) the step of dissolving the precipitated one or more protein contaminants in a suitable solvent. In some embodiments, the concentration of one or more protein contaminants further comprises the step of reducing the volume of the fraction containing one or more protein contaminants before the precipitation of one or more protein contaminants.
[0083] Accordingly, in a specific embodiment, the method comprises the step of applying a fraction containing one or more protein contaminants to the concentration of one or more protein contaminants, wherein the concentration of one or more protein contaminants comprises the step of precipitating one or more protein contaminants; and the step of dissolving one or more precipitated protein contaminants in a suitable solvent.
[0084] In a further specific embodiment, the method comprises the step of applying a fraction containing one or more protein contaminants to the concentration of one or more protein contaminants, wherein the concentration of one or more protein contaminants comprises the step of precipitating one or more protein contaminants after reducing the volume of the fraction containing one or more protein contaminants; and the step of dissolving the precipitated one or more protein contaminants in a suitable solvent.
[0085] Volume reduction can be achieved by various suitable methods known to those skilled in the art. In one embodiment, volume reduction of a fraction containing one or more protein contaminants involves the use of a molecular weight cut-off (MWCO) filter. In a specific embodiment, the molecular weight cut-off filter has a molecular weight cut-off of about 2 kDa to about 30 kDa, about 3 kDa to about 25 kDa, about 4 kDa to about 20 kDa, or about 5 kDa to about 15 kDa. In a preferred embodiment, the molecular weight cut-off filter has a molecular weight cut-off of about 5 kDa to about 15 kDa. In a further embodiment, the molecular weight blocking filter has a molecular weight block of about 5 kDa, about 6 kDa, about 7 kDa, about 8 kDa, about 9 kDa, about 10 kDa, about 11 kDa, about 12 kDa, about 13 kDa, about 14 kDa, or about 15 kDa. In a preferred embodiment, the molecular weight blocking filter has a molecular weight block of about 10 kDa.
[0086] After precipitating one or more protein contaminants, the precipitated one or more protein contaminants are generally settled (e.g., by centrifugation), and the supernatant is removed and discarded. The resulting protein pellet contains the analyte of interest, namely one or more protein contaminants, and is used for further processing and analysis as described herein. Accordingly, in some embodiments, after precipitating one or more protein contaminants, the precipitated one or more protein contaminants are settled and the supernatant is removed. After settling, the resulting protein pellet may be dried. Drying may be performed by conventional methods known to a person skilled in the art, such as air drying, freeze-drying, or vacuum centrifugation.
[0087] Precipitation of proteins can be achieved by various means known to those skilled in the art. In some embodiments, the precipitation of one or more protein contaminants includes a step of adding a precipitating agent. Preferably, the precipitating agent is selected from the group consisting of trichloroacetic acid (TCA), acetone, ammonium sulfate, a combination of chloroform and methanol and water, and a combination of chloroform and methanol. In a further preferred embodiment, the precipitating agent is acetone. The precipitating agent may be cooled, i.e., to a temperature between about 2°C and about 8°C, for example, about 4°C.
[0088] A precipitating agent (precipitating agent) added for the purpose of precipitating one or more protein contaminants is generally added in an amount sufficient to cause complete or essentially complete precipitation of the protein contained in a fraction containing one or more protein contaminants. In some embodiments, the precipitation of one or more protein contaminants comprises the step of adding a precipitating agent in an amount of at least about 2:1, at least about 3:1, at least about 4:1, or at least about 5:1 with respect to the volume of a fraction containing one or more protein contaminants (optional after volume reduction of said fraction and / or addition of an aqueous salt solution). In a preferred embodiment, the precipitation of one or more protein contaminants comprises the step of adding a precipitating agent in an amount of at least about 2:1 with respect to the volume of a fraction containing one or more protein contaminants (optional after volume reduction of said fraction and / or addition of an aqueous salt solution). In a further preferred embodiment, the precipitation of one or more protein contaminants comprises the step of adding a precipitating agent in an amount of at least about 3:1 with respect to the volume of a fraction containing one or more protein contaminants (optional, after volume reduction of said fraction and / or addition of an aqueous salt solution) (e.g., adding at least 300 μL of the agent to 100 μL of a fraction containing one or more protein contaminants). In a more preferred embodiment, the precipitation of one or more protein contaminants comprises the step of adding a precipitating agent in an amount of at least about 4:1 with respect to the volume of a fraction containing one or more protein contaminants.
[0089] The precipitation of one or more protein contaminants may involve the addition of an aqueous salt solution. Preferably, the addition of the aqueous salt solution is performed prior to the addition of the precipitating agent. More preferably, the aqueous salt solution is an aqueous solution of a salt selected from the group consisting of NaCl. In a preferred embodiment, the aqueous salt solution is an aqueous solution of NaCl. The salt contained in the aqueous salt solution is not a precipitating agent as disclosed herein, and is not, for example, ammonium sulfate.
[0090] In some embodiments, the aqueous salt solution contains the salt at a concentration of about 50 mM to about 500 mM, about 100 mM to about 400 mM, or about 150 mM to about 300 mM. In a preferred embodiment, the aqueous salt solution contains the salt at a concentration of about 150 mM to about 300 mM. In further embodiments, the aqueous salt solution contains the salt at a concentration of about 100 mM, about 200 mM, about 300 mM, about 400 mM, or about 500 mM. In a preferred embodiment, the aqueous salt solution contains the salt at a concentration of about 200 mM.
[0091] After adding a precipitating agent (precipitating agent) for precipitating one or more protein contaminants, the resulting suspension may be maintained at a low temperature before further treatment (e.g., before the precipitation of one or more precipitated protein contaminants) to facilitate protein precipitation. In some embodiments, the suspension is maintained at a temperature of about -20°C or lower for at least about 5 minutes. In some embodiments, the suspension is maintained at a temperature of about -60°C or lower for at least about 8 minutes. In some embodiments, the sample is maintained at a temperature of about -65°C or lower for at least about 10 minutes.
[0092] The sedimentation of one or more precipitated protein contaminants is generally achieved by centrifugation. In some embodiments, the sedimentation of one or more precipitated protein contaminants comprises the step of centrifuging at a centrifugal force of at least about 10,000 g for at least about 5 minutes. In further embodiments, the sedimentation of one or more precipitated protein contaminants comprises the step of centrifuging at a centrifugal force of at least about 14,000 g for at least about 10 minutes. Centrifugation may be performed at a temperature lower than room temperature, for example, about 2°C to about 8°C, for example, about 4°C.
[0093] Accordingly, in some embodiments, the method according to the present invention comprises the following:
[0094] (a) a fractionation step of a sample comprising a recombinant protein and one or more protein contaminants, wherein the fractionation comprises the step of contacting the sample with an Fc receptor affinity resin and collecting the pass-through to obtain a fraction comprising one or more protein contaminants;
[0095] (b) a step of analyzing one or more protein contaminants in a fraction containing one or more protein contaminants, wherein the analysis comprises:
[0096] A step of applying a fraction containing one or more protein contaminants to the concentration of one or more protein contaminants, wherein the concentration of one or more protein contaminants reduces the volume of the fraction containing one or more protein contaminants, then adds an aqueous salt solution, then adds a precipitating agent selected from the group consisting of trichloroacetic acid (TCA), acetone, ammonium sulfate, a combination of chloroform and methanol and water, and a combination of chloroform and methanol to precipitate one or more protein contaminants, then maintains the resulting suspension at a low temperature, then settles the precipitated one or more protein contaminants (e.g., by centrifugation), removes the supernatant, and discards the supernatant; and dissolves the precipitated one or more protein contaminants in a suitable solvent.
[0097] Dissolve one or more precipitated protein contaminants in a suitable solvent. The suitable solvent and possible additives should generally be compatible with the subsequent chemical reduction and protein hydrolytic digestion, that is, they should not interfere with either of these reactions.
[0098] A suitable solvent is preferably a suitable aqueous buffer. A suitable aqueous buffer is typically based on an ammonium salt. The buffer salt may be selected from the group consisting of ammonium formate, Tris-HCl, ammonium acetate, and ammonium bicarbonate or ammonium carbonate. In a preferred embodiment, the aqueous buffer is an aqueous solution of ammonium bicarbonate. The concentration of the aqueous buffer may be about 10 mM to about 100 mM, about 20 mM to about 90 mM, about 30 mM to about 70 mM, or about 40 mM to about 60 mM. In a specific embodiment, the concentration of the aqueous buffer is about 50 mM. In some embodiments, the pH of the aqueous buffer is about 7 to about 9, preferably about 7.0 to about 9.0. In a preferred embodiment, the pH of the aqueous buffer is about 7.4 to about 8.6. In a more preferred embodiment, the pH of the aqueous buffer is about 7.6 to about 8.4. In a particularly preferred embodiment, the pH of the aqueous buffer is about 8, more preferably about 8.0.
[0099] Accordingly, in a preferred embodiment, the aqueous buffer is an aqueous ammonium bicarbonate solution, wherein the buffer concentration is about 10 mM to about 100 mM and the pH of the aqueous buffer is about 7 to about 9, preferably about 7.0 to about 9.0. In a particularly preferred embodiment, the aqueous buffer is an aqueous ammonium bicarbonate solution, wherein the buffer concentration is about 50 mM and the pH of the aqueous buffer is about 8, preferably about 8.0.
[0100] A suitable solvent may be an aqueous buffer containing a surfactant. At least one surfactant is preferably one that does not interfere with subsequent analysis by liquid chromatography-mass spectrometry. At least one surfactant may be N-octyl-beta-glucopyranoside, sodium deoxycholate, N-dodecyl-beta-D-maltoside, or a combination thereof. In some embodiments, the suitable solvent is an aqueous buffer containing a surfactant, and preferably, said surfactant is selected from the group consisting of sodium deoxycholate, N-dodecyl-beta-D-maltoside, and combinations thereof. In a particularly preferred embodiment, the surfactant is a combination of sodium deoxycholate and N-dodecyl-beta-D-maltoside.
[0101] The surfactant is preferably used at a concentration that does not interfere with subsequent analysis by liquid chromatography-mass spectrometry. In a specific embodiment, the aqueous buffer contains the surfactant at a concentration of about 0.05% to about 1.0% (w / v). Sodium deoxycholate (SDC) may be used at a concentration ranging from about 0.05% to about 0.8% (w / v). N-dodecyl-beta-D-maltoside may be used at a concentration ranging from about 0.01% to about 0.5% (w / v). Thus, in a specific embodiment, the aqueous buffer contains sodium deoxycholate at a concentration of about 0.05% to about 0.8% (w / v) and N-dodecyl-beta-D-maltoside at a concentration of about 0.01% to about 0.5% (w / v). In a preferred embodiment, the aqueous buffer contains sodium deoxycholate at a concentration of about 0.1% to about 0.6% (w / v) and N-dodecyl-beta-D-maltoside at a concentration of about 0.04% to about 0.5% (w / v). In a more preferred embodiment, the aqueous buffer contains sodium deoxycholate at a concentration of about 0.2% to about 0.4% (w / v) and N-dodecyl-beta-D-maltoside at a concentration of about 0.05% to 0.5%, preferably about 0.06% to about 0.2% (w / v).
[0102] In some embodiments, the analysis of step b) includes a fragmentation step of one or more protein contaminants. In a preferred embodiment, the fragmentation step of one or more protein contaminants is performed by protein hydrolytic digestion. In some embodiments, the method includes a step of chemically reducing one or more protein contaminants before or after fragmentation, preferably before fragmentation.
[0103] Accordingly, in some embodiments, the method includes a step of chemically reducing one or more protein contaminants and then fragmenting one or more protein contaminants by protein hydrolytic digestion.
[0104] In a specific embodiment, the method comprises: (a) a fractionation step of a sample comprising a recombinant protein and one or more protein contaminants, wherein the fractionation comprises the step of contacting the sample with an Fc receptor affinity resin and collecting the pass-through to obtain a fraction comprising one or more protein contaminants; and (b) an analysis step of one or more protein contaminants in a fraction comprising one or more protein contaminants, wherein the analysis comprises the step of applying the fraction comprising one or more protein contaminants to a concentration of one or more protein contaminants—wherein the concentration of one or more protein contaminants comprises the step of precipitating one or more protein contaminants and dissolving the precipitated one or more protein contaminants in a suitable solvent—; a step of chemically reducing one or more protein contaminants; and subsequently a step of fragmenting one or more protein contaminants by proteolytic digestion.
[0105] Any conventional agent for chemical reduction prior to mass spectrometry may be used in the method of the present invention. In some embodiments, chemical reduction involves the use of a reducing agent selected from the group consisting of dithiothreitol (DTT), tris(3-hydroxypropyl)phosphine (THPP), and tris2-carboxyethylphosphine (TCEP). In preferred embodiments, chemical reduction involves the use of dithiothreitol (DTT) or tris2-carboxyethylphosphine (TCEP). In particularly preferred embodiments, chemical reduction involves the use of tris2-carboxyethylphosphine (TCEP).
[0106] The reducing agent is used at a concentration that quantitatively or essentially quantitatively reduces the peptide in the sample. In some embodiments, the reducing agent is used at a final concentration of about 1 mM to about 10 mM, about 2 mM to about 9 mM, about 3 mM to about 7 mM, or about 4 mM to about 6 mM. In a preferred embodiment, the reducing agent is used at a final concentration of about 3 mM to about 7 mM. In a more preferred embodiment, the reducing agent is used at a final concentration of about 4 mM to about 6 mM.
[0107] Chemical reduction of a protein or peptide for subsequent mass spectrometry is typically performed at an elevated temperature. Accordingly, in some embodiments, chemical reduction is performed at about room temperature to about 60°C, preferably about 40°C to about 60°C. In a more preferred embodiment, chemical reduction is performed at about 45°C to about 55°C. In an even more preferred embodiment, chemical reduction is performed at about 50°C.
[0108] Protein hydrolytic digestion for subsequent mass spectrometry can generally be achieved using a protease that produces a regular cleavage pattern. In some embodiments, protein hydrolytic digestion comprises a step of using a protease selected from the group consisting of trypsin, chymotrypsin, ArgC, GluC, AspN, LysC, LysN, elastase, proteinase K, and combinations thereof. In some embodiments, protein hydrolytic digestion involves the use of one specific protease (e.g., trypsin). In some embodiments, protein hydrolytic digestion involves the use of a combination of two specific proteases (e.g., trypsin and LysC). In a preferred embodiment, protein hydrolytic digestion involves the use of trypsin and LysC. In a further preferred embodiment, protein hydrolytic digestion involves the use of trypsin.
[0109] The protease used for protein hydrolytic digestion prior to mass spectrometry is used at its respective optimal temperature (e.g., about 37°C). Accordingly, in some embodiments, protein hydrolytic digestion is performed at a temperature between about 30°C and about 60°C, preferably between about 34°C and about 40°C, more preferably between about 35°C and about 39°C, and much more preferably between about 36°C and about 38°C. In a particularly preferred embodiment, protein hydrolytic digestion is performed at a temperature of about 37°C.
[0110] Proteases may be used in varying amounts. In some embodiments, protein hydrolytic digestion comprises the step of using one or more proteases in a ratio between about 1:5 and about 1:100, preferably about 1:5 and about 1:40, more preferably about 1:10 and about 1:30, and much more preferably about 1:15 and about 1:25 (w / w, protease(s) to protein substrate). In a particularly preferred embodiment, protein hydrolytic digestion comprises the step of using one or more proteases in a ratio of about 1:20 (w / w, protease(s) to protein substrate).
[0111] In some embodiments, protein hydrolytic digestion is carried out for at least about 15 minutes. In additional embodiments, protein hydrolytic digestion is carried out for at least about 30 minutes. In further embodiments, protein hydrolytic digestion is carried out for at least about 45 minutes. In further embodiments, protein hydrolytic digestion is carried out for at least about 60 minutes. With respect to duration, protein hydrolytic digestion may be carried out overnight. In preferred embodiments, protein hydrolytic digestion is carried out for between about 15 minutes and about 90 minutes. In more preferred embodiments, protein hydrolytic digestion is carried out for between about 30 minutes and about 60 minutes.
[0112] The above method may further include the identification and / or quantification of one or more individual protein contaminants within a fraction containing one or more protein contaminants.
[0113] In one embodiment, the analysis of one or more protein contaminants in step b) includes one or more individual protein contaminant identification steps, preferably the identification is performed by peptide analysis by liquid chromatography-mass spectrometry (LC-MS). In some embodiments, the liquid chromatography-mass spectrometry is liquid chromatography-tandem mass spectrometry (LC-MS / MS).
[0114] In some embodiments, the method according to the present invention comprises: (a) a fractionation step of a sample comprising a recombinant protein and one or more protein contaminants, wherein the fractionation comprises contacting the sample with an Fc receptor affinity resin and collecting the pass-through to obtain a fraction comprising one or more protein contaminants; and (b) an analysis step of one or more protein contaminants in a fraction comprising one or more protein contaminants, wherein the analysis comprises applying the fraction comprising one or more protein contaminants to a concentration of one or more protein contaminants, wherein the concentration of one or more protein contaminants comprises precipitating one or more protein contaminants and dissolving the precipitated one or more protein contaminants in a suitable solvent; a step of chemically reducing one or more protein contaminants; subsequently fragmenting one or more protein contaminants by proteolytic digestion; and identifying one or more individual protein contaminants by peptide analysis by liquid chromatography-mass spectrometry (LC-MS).
[0115] As used herein, mass spectrometry (MS) refers to an analytical technique that filters, detects, identifies, and / or measures compounds according to their mass-to-charge ratio, “Da / e” (commonly denoted by the symbol “m / z”). MS techniques generally include (1) the step of ionizing the compound and potentially fragmenting the compound; and (2) the step of detecting the molecular weight of the charged compound and / or fragment ions and calculating the mass-to-charge ratio (m / z). Compounds may be ionized and detected by any suitable means. Mass spectrometers generally include an ionizer and an ion detector.
[0116] Tandem mass spectrometry (MS / MS) refers to a mass spectrometry method in which a parent ion generated from a sample is selected by a first mass filter / analyzer and passed through a collision cell, where it is fragmented by collision with neutral gas molecules to produce daughter (or “product”) ions. Subsequently, the daughter ions are mass-analyzed by a second mass filter / analyzer, and the structure is determined using the spectrum of the generated daughter ions, thereby identifying the parent (or “precursor”) ion. Tandem mass spectrometry is particularly useful for the analysis of complex mixtures, such as biomolecules.
[0117] As used herein, liquid chromatography (LC) refers to a process in which one or more components of a fluid solution are selectively retained as the fluid passes uniformly through a column of finely divided material or a capillary passage. Retention occurs as components of a mixture are distributed between one or more stationary phases and the bulk fluid (i.e., mobile phase) as the fluid moves relative to the stationary phase(s). Liquid chromatography includes, without limitation, reverse phase liquid chromatography (RPLC), high performance liquid chromatography (HPLC), ultra-high performance liquid chromatography (UHPLC), supercritical fluid chromatography (SFC), and ion chromatography. In some embodiments, the liquid chromatography performed as part of an LC-MS analysis is reverse-phase (RP) liquid chromatography.
[0118] RP chromatography is based on a nonpolar stationary phase and a polar mobile phase. The stationary phase typically used in reversed-phase (RP) liquid chromatography comprises a silica resin functionalized with various nonpolar functional groups, such as alkyl groups. The surface of the alkyl functionalized resin may comprise a C-4, C-8, or C-18 functionalized resin, preferably a C-18 functionalized resin.
[0119] Peptide analysis by liquid chromatography-mass spectrometry (LC-MS) can be performed using various suitable instruments. Suitable LC-MS instruments are known to those skilled in the art and include, for example, the Orbitrap mass spectrometer of Thermo Fisher Scientific Inc.
[0120] A solvent system suitable for reverse-phase liquid chromatography comprises a mobile phase consisting of water and an organic solvent (e.g., methanol, ethanol, propanol, or acetonitrile) in varying proportions. The mobile phase may optionally include a pH adjuster such as acetic acid, formic acid, trifluoroacetate, water ammonia, ammonium acetate, ammonium formate, or a combination thereof. In a preferred embodiment, the mobile phase comprises water, acetonitrile, and formic acid.
[0121] After mass spectrometry, the peptide is mapped to a peptide database corresponding to one or more sources of protein contaminants, for example, the cell line used to produce the recombinant protein. Protein sequence data is publicly available, for example, at uniprot.org. For example, the CHO reference proteome is deposited under reference number UP000001075. Sequences of common contaminants, such as keratin, trypsin (UniProt ID P00761), and recombinant protein sequences, can be added to the reference proteome used. The software uses the same protease(s) (e.g., trypsin) used for the proteolytic digestion of the protein contaminants against proteins in the database In silico Digestion is performed. The masses of these peptides are calculated and compared with a list of peaks of the measured masses. If the protein sequences in the reference database yield a significant number of predicted masses that match the experimental masses, it serves as evidence that this protein was present in the original sample. Peptides can be fragmented by MS / MS to provide higher-quality data and enable more definitive peptide identification. The results are statistically analyzed, and one or more protein contaminants in the sample are identified and selectively quantified using possible matches.
[0122] Accordingly, in some embodiments, peptide analysis and identification of individual protein contaminants by liquid chromatography-mass spectrometry (LC-MS) refer to the mass spectrometry data of the proteome. In silico It includes a step of comparing with a database of peptides generated by protein hydrolysis digestion.
[0123] It will be apparent to a person skilled in the art that these embodiments and items represent only examples of a plurality of possibilities. Accordingly, the embodiments presented herein should not be understood as limiting these features and configurations. Any possible combination and configuration of the described features may be selected according to the scope of the invention.
[0124] Examples
[0125] Materials and Methods
[0126] chemical
[0127] Tris 2-carboxyethylphosphine (TCEP), ammonium bicarbonate (ABC), ultrapure formic acid, acetic acid, guanidine-HCl, chloroform, methanol, acetonitrile (ACN), water, trifluoroacetic acid (TFA), sodium deoxycholate (SDC), and universal proteomics standard (UPS-1) were purchased from Sigma-Aldrich (St. Louis, MO). Vivaspin 500 (10 kDa MWCO) was purchased from Cytiva (Marlborough, MA). Sequence-grade trypsin / Lys-C mixture and N-dodecyl-beta-D-maltoside (DDM) were purchased from Promega (Milwaukee, WI) and Thermo Fisher Scientific (Waltham, MA), respectively. IdeS and FabALACTICA were purchased from Genovis. PNGaseF was purchased from New England BioLabs.
[0128] Sample preparation for affinity chromatography
[0129] mAb1 samples were produced in-house at Lonza using recombinant expression technology and standard purification procedures with CHO cell lines. mAb2 samples (8670 NIST mAb) were purchased from NIST. N-glycans were removed from the samples after incubation with PNGase F at 37°C for 3 hours. Fc and Fc / 2 fragments of mAb2 were prepared by digestion with FabALACTICA and IdeS, respectively, in accordance with the manufacturer's recommendations.
[0130] Affinity chromatography
[0131] The pass-through (FT) fraction was collected using an FcR-IIIA-5PW 7.8 mm x 7.5 cm column (P / N 0023532, TOSOH Bioscience, King of Prussia, PA). Mobile phase A was 50 mM citrate at pH 6.5, and mobile phase B was 50 mM citrate at pH 4.5. The buffer was exchanged with mobile phase A three times prior to injecting all samples. Samples were injected at a flow rate of 0.3 mL / min under conditions of a column temperature of 15°C and UV detection at 280 nm.
[0132] To reduce HPLC run time, the gradient elution step was changed to a trap-and-elution method as follows: after loading with 100% mobile phase A for 15 minutes, the gradient was switched to 100% B for 1 minute, followed by maintaining the flow rate at 0.4 mL / min for 30 minutes. Before starting a new injection, the column was equilibrated with 100% mobile phase A for 27 minutes.
[0133] Protein A chromatography was performed using a HiTrap MabSelect SuRe column according to the previously reported procedure [3]. Figure 8 illustrates the steps in more detail.
[0134] Sample preparation for peptide mapping analysis
[0135] Protein precipitation by acetone
[0136] The FT fraction (about 3.0 mL) collected during affinity chromatography was concentrated into about 100 μL of concentrate by centrifuging at 10,000 g and 20°C for about 20 minutes using a Vivaspin filter with a 10 kDa blocking membrane. The protein in the concentrate was precipitated with acetone using a procedure similar to that described by Jiang et al. [4]. Briefly, the sample was diluted with 200 mM NaCl (1:1), then 800 μL of cold acetone (4°C) was added to the sample, and the solution was incubated in a freezer at ≤ -65°C for 10 minutes. After centrifugation for 10 minutes (at 14,000 g and 4°C), the liquid was carefully removed and discarded, and the remaining protein pellet was used for the preparation of the proteome sample.
[0137] Trypsin digestion
[0138] The protein pellet was dissolved in 15 μL of a 50 mM ammonium bicarbonate solution containing SDC (2.3% w / v) and DDM (0.66% w / v). After vortex mixing at room temperature, the mixture was diluted by adding an additional 74 μL of the 50 mM ammonium bicarbonate solution. 1 μL of 500 mM TCEP was added, and the solution was incubated at 50°C for 10 minutes to reduce the protein. The sample was digested with a trypsin / LysC mixture (enzyme-to-protein ratio 1:20; trypsin:LysC ratio could be 1:1 (w / w)) at 37°C for 1 hour, and then transferred directly to an HPLC vial for LC-MS / MS analysis as described below. The final concentrations of SDC and DDM prior to injection were 0.35% w / v and 0.1% w / v, respectively. The amount of protease required for digestion was calculated based on the assumption that the HCP in the material loaded on the FcγRIIIa column was 200 ppm.
[0139] Liquid Chromatography-Mass Spectrometry
[0140] A system consisting of a Vanquish Neo UHPLC instrument coupled to an Orbitrap Fusion Lumos mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) was used for LC-MS / MS analysis. For peptide mapping analysis, NanoEase m / z Peptides in the digested sample were separated using a Peptide CSH C18 column (130 Å, 1.7 μm, 0.3 mm x 150 mm, Waters Corporation) with a mobile phase consisting of 0.1% formic acid (A) and acetonitrile (B) in water. Peptides were separated and eluted at a flow rate of 5 μL / min using a linear gradient from 1% B to 40% B for 75 minutes, followed by 98% B for 5 minutes. Subsequently, the column was washed with 98% B for 3 minutes and equilibrated with 1% B for 10 minutes before the next injection.
[0141] The mass spectrometer was operated in data-dependent mode in the 200–2000 m / z range, at a spray voltage of 3500 kV, and a heated capillary temperature of 325°C. Automatic gain control (AGC) target value 2.0 x 10⁻¹⁰ 5 The full scan spectrum was recorded with a resolution of 120,000 (full width at half maximum resolution at 400 m / z) using a maximum injection time of 100 ms. Up to 20 of the strongest ions with charge states 2–8 were selected for high-energy C-trap dissociation (HCD) at 30% normalized collision energy. AGC target value 5.0 x 10⁻⁶ ⁴ Fragment spectra were recorded with a separation width of 2.5 Da and a resolution of 15,000 using a maximum injection time of 200 ms. Dynamic exclusion was enabled for 20 seconds within a 10 ppm interval for precursor selection. Fragment ions were recorded on an Orbitrap analyzer.
[0142] Data analysis
[0143] For peptide mapping, tolerances of 5 ppm and 20 ppm were applied to database searches for peptides identified in MS and MS / MS analyses, respectively. Searches were performed on the CHO protein sequence database obtained from UniProt (Reference Proteome UP000001075, last modified on 2019-01-24, downloaded on 2022-10-10 containing 23,886 sequences), to which sequences of common contaminants such as keratin and trypsin (UniProt ID P00761) and sequences of analyzed mAbs were added. Methionine and tryptophan oxidation, and asparagine deamidation were included in the search as variable modifications. The false discovery rate (FDR) was set to 2%.
[0144] Example 1: mAb depletion using FcγRIIIa affinity chromatography
[0145] In this application, mAb1 (IgG4) and mAb2 (IgG1) were used as proof-of-concept samples. Thus, the ability of these to be retained in an FcγRIIIa affinity column was evaluated when the Fc domain was glycosylated and when it was not glycosylated. After exchanging the buffer with mobile phase A, the samples were loaded onto an FcγRIIIa affinity column. As described in the Materials and Methods section, the gradient elution step was changed to a trap-and-elution approach. Error! Reference source not found. Figures A and 2B show the retention of mAb1 and mAb2 in their natural forms (dotted line) and deglycosylated forms (solid line) by an FcγRIIIa affinity column. The deglycosylated mAb had low binding affinity to the column and eluted as the FT fraction.
[0146] The suitability of the present method for analyzing HCP based on therapeutic mAb fragments was also evaluated. To generate smaller fragments, mAb2 was digested using the enzymes IdeS and FabALACTICA, which cleave the mAb above and below the hinge region. Subsequently, the ability of the FcγRIIIa resin to retain smaller fragments having Fc domain glycosylation was evaluated (Figs. 3 and 4).
[0147] Error! Reference source not found. As shown in A, FabALACTICA can produce both Fab and Fc fragments. The FcγRIIIa affinity chromatogram of this digest showed two peaks: one eluted as the FT fraction at a retention time (RT) of 8.3 min (collected as Fraction 1), and the other eluted as a multiple peak at RT 30–45 min (collected as Fraction 2). Error! Reference source not found. A). The two collected fractions were concentrated using a blocking filter (10 kDa) and analyzed by RP-LC-MS. The total ion current (TIC) of each fraction is Error! Reference source not found. B and Error! Reference source not found. It is illustrated in C. The unwound mass spectrum of TIC indicated the estimated molecular weight of the detected fragment ( Error! Reference source not found. D and 3E). The results confirmed that the Fab fragment did not show affinity for the FcγRIIIa affinity column and subsequently eluted as an FT fraction.
[0148] IdeS cleaves the mAb at a single site below the hinge region. Error! Reference source not found. As illustrated in A, it generates F(ab')2 and Fc / 2 fragments. Surprisingly, the FcγRIIIa chromatogram of mAb1 digested with IdeS showed a single peak eluted into the FT fraction at RT 8.0 min. RP-LC-MS analysis of this fraction revealed two well-separated peaks (RT 14.8 min and 16.8 min). The unwound MS spectra of each peak are Error! Reference source not found.The existence of Fc / 2 and F(ab)'2 fragments was confirmed as shown in C and 4D, respectively.
[0149] The presence of a single peak in the FcγRIIIa chromatogram, followed by the identification of the Fc / 2 fragment in the collected fraction by RP-LC-MS, indicated that the Fc / 2 fragment had no binding affinity for the FcγRIIIa resin or at least a low affinity and was eluted into the FT fraction.
[0150] These results demonstrate that Fc receptors immobilized on FcγRIIIa columns have a lower ability to bind to smaller mAb fragments containing glycosylated Fc domain fragments (e.g., Fc / 2). The best results were obtained with antibodies containing the full-length Fc domain (e.g., IgG isotype antibodies). These results also demonstrate whether and how an Fc affinity resin, i.e., an Fc receptor, can be identified and selected to match a selected and given recombinant protein, thereby demonstrating that the selected and given recombinant protein is effectively bound to and retained by the Fc resin, while any protein contaminants can be separated from the recombinant protein bound to the resin and collected from the pass-through for analysis. The interaction profiles of different types of Fc receptors are known to those skilled in the art. For example, Russell et al. discuss the binding profiles of various types of Fc receptors
[13] . The majority of currently approved mAb therapeutics belong to the IgG1 and 4 subclasses. Therefore, the disclosed method may be widely useful for characterizing HCPs in commercially relevant antibody formulations.
[0151] Example 2: Rapid digestion for high-throughput HCP analysis
[0152] The digestion procedure of the present invention has the advantages of short processing time, efficiency, and high throughput. Since only trace amounts are typically present in the final product, sample loss can be a major issue in the proteomic analysis of HCP. Therefore, considering that at least two to three unique peptides are required for the identification and quantification of HCP, it is difficult to apply general traditional sample processing workflows. To evaluate the digestion quality of the present approach for identifying low-level HCP, UPS1 was reduced and digested for up to 60 minutes according to the procedure described in Materials and Methods, and measurements were acquired at 15-minute intervals. UPS1 contains a mixture of 48 proteins at equimolar concentrations, with molecular weights (MW) ranging from 6.3 to 82.9 kDa. To further investigate digestion quality, the average protein sequence coverage, the number of identified proteins, and the sum of protein signal intensities were compared at each time point (Fig. 5).
[0153] Error! Reference source not found. This summarizes the total signal intensity, labeled as “Total Peptide MS Intensity,” and average sequence coverage (displayed as percentages at the top of each of the four columns) for each investigated digestion condition. With a digestion time of 15 minutes, 47 out of 48 UPS1 proteins were identified (the number of identified proteins is the height of each bar, and the scale is labeled “Number of Detected Proteins” on the left). The four different shades of each bar represent the percentage of sequence coverage: when the proteins were digested for 15 minutes, most were identified with an average sequence coverage of 45%. As the digestion time was increased to a maximum of 45 minutes, the average sequence coverage increased from 42% to 64%, and the identification signal intensity also increased ( Error! Reference source not found. ).
[0154] The slight decrease in sequence coverage and peptide MS intensity after 60-minute digestion compared to 30- and 45-minute digestions indicates that the percentage of completely cleaved peptides (where the peptide has more than one cleavage site) increases with longer digestion times. This results in, on the one hand, very short peptides that are not retained in the RP column, but on the other hand, individual completely cleaved peptide fragments that are well retained in the RP column and provide superior and more reliable identification and quantification results. Therefore, 60-minute digestion improved the overall throughput associated with digestion completion while imparting higher intensity to peptides without missed cleavages. This methodology is robust, low-cost, and is expected to improve the throughput of HCP analysis.
[0155] Example 3: HCP analysis of isolated fractions from FcγRIIIa affinity chromatography
[0156] A semi-preparative FcγRIIIa affinity column was used for a larger loading capacity, which allowed a larger amount of sample to be loaded into the column and required only a single run to collect sufficient material for proteomic analysis. Following the steps outlined in Materials and Methods, 5 mg of the mAb1 sample was buffered with FcγRIIIa loading buffer (mobile phase A) and loaded onto the FcγRIIIa affinity column ( Error! Reference source not found. The FT fraction was collected (Fraction 1), concentrated, and the protein was precipitated with acetone. Then, as described in Materials and Methods, the protein was digested using a trypsin / Lys-C mixture and analyzed using LC-MS / MS.
[0157] The protein / enzyme ratio was calculated assuming that the sample loaded on the FcγRIIIa column contains 200 ppm of HCP. The above value can be adjusted to be applied to samples from different purification processes. Identification of HCP was based on the identification of at least one unique peptide having at least five amino acid residues.
[0158] For data analysis, a strategy similar to recently reported ones was used with slight adjustments as described below [3]. Peptide identification was extended to the full-scan MS level only when peptides were detected by MS / MS in different fractions of the same mAb. To re-evaluate these “in silicopeptides,” the following criteria were used: a retention time difference of less than 30 seconds in the same sequence, a mass accuracy of 5 ppm for peptide mass, an MS1 correlation of 0.90, and 5 x 10⁻¹⁰ 4 ≥ 5 x 10 4 ) signal intensity, and the experimental isotope pattern of the identified peptide is in good agreement with the theoretical mean distribution.
[0159] A total of 63 HCPs were identified as at least one unique peptide. A summary of the HCPs found by the FcγRIIIa affinity column is presented in Table 1.
[0160] The major identified HCPs with at least 15% sequence coverage were phospholipase B-like protein (PLBL2), protein S100, CC motif chemokine, glutathione S-transferase P, and heat shock homologue 71 kDa protein. The maximum signal intensity of the identified HCPs corresponded to PLBL2 with 72.5% sequence coverage.
[0161] In addition to PLBL2, the light chain (LC) and heavy chain (HC) were identified with more than 90% amino acid sequence coverage. The FcγRIIIa column efficiently depletes mAb1, but product-related impurities, such as fragments (e.g., LC or HC without an Fc domain), do not bind to the column and are washed out as the FT fraction (HCP-rich fraction).
[0162] [Table 1]
[0163] HCP identified in mAb 1 after depletion by protein A or FcγRIIIa affinity column.
[0164]
[0165]
[0166]
[0167] Example 4: HCP Analysis of Fraction Isolated from Protein A Affinity Chromatography: Fcγ RIIIa Comparison with Affinity Chromatography
[0168] Protein A affinity chromatography has frequently been used as a general approach to deplete mAbs prior to proteomic studies of HCPs [3]. Protein A-based separation relies on the strong affinity of the mAb Fc region to bind to the Protein A resin under neutral pH conditions, while most HCPs and other impurities are washed away and evaporated into the FT fraction. Despite Protein A's excellent ability to deplete mAbs, the utility of this approach in proteomic workflows is reduced because the chromatographic resin and mAbs interact non-specifically with specific HCPs. HCP-mAb interactions can involve various forces, including electrostatic interactions, hydrogen bonding, hydrophobic interactions, and / or van der Waals forces. These interactions can hinder the complete removal of various types of HCPs by Protein A chromatography, as the HCPs elute along with the mAbs. To prevent these interactions, a pre-elution wash step is commonly applied before eluting mAbs in protein A chromatography. To improve HCP recovery and prevent specific risk levels for root cause investigation prior to proteomic analysis, the effectiveness of the pre-elution wash for each mAb must be evaluated [3]. However, when rapid processing times are required, optimizing product-specific pre-elution washes is typically a major bottleneck for biopharmaceutical companies.
[0169] Although both FcγRIIIa and protein A resins can be used in affinity chromatography, potentially equivalent non-specific interactions in protein A-based purification methods have not been studied for FcγRIIIa chromatography. Therefore, the inventors investigated how efficiently HCP is isolated when using FcγRIIIa chromatography and protein A chromatography.
[0170] To this end, 5 mg of mAb1 was injected into a protein A affinity column according to a recently described procedure [3]. The FT fraction (referred to as “F1-protein A”) was collected, and the column was rinsed with water. Pre-elution was performed at a basic pH in the presence of a high concentration of salt (referred to as “F2-protein A”) [3]. Finally, mAb1 was eluted from the column using glycine buffer at pH 2.80 (referred to as “F3-protein A”). Figure 8 shows a schematic diagram of the protein A workflow.
[0171] The FT and pre-elution fractions (F1-Protein A and F2-Protein A) collected during protein A affinity chromatography were concentrated, precipitated, and digested as described in Materials and Methods, i.e., in a manner similar to the FT treatment from FcγRIIIa chromatography.
[0172] When comparing the protein identification results according to each approach, 57 HCPs were identified in the protocol using protein A, whereas 63 proteins were identified in Example 3 in the Fc receptor-based method of the present invention.
[0173] Similar to the Fc receptor approach, PLBL2 was detected in the Protein A fractions (F1- and F2-Protein A) with sequence coverage exceeding 70%. PLBL2 is known as the “Hitchhiker HCP” because it is difficult to remove even after multiple chromatographic steps and can trigger an immune response in patients. To better understand HCP-mAb interactions, PLBL2 levels were evaluated in the FcγRIIIa and Protein A affinity chromatographic fractions.
[0174] First, the MS peak areas of all PLBL2 peptides detected in the Protein A fractions (F1-, F2-, and F3-Protein A) were calculated. According to the data, F2-Protein A and F3-Protein A were 93.9%, respectively (Sum of MS signals: 3.8 x 10⁻⁶ 9 ) and 0.6%( Sum of MS signals: 2.6 x 10 7 It showed the peak and trough signal intensities (Fig. 7A). The relevance of the pre-elution step was 5.5% of the total PLBL2 signal in F1-protein A (Sum of MS signals: 2.2 x 10⁻⁶). 8 This was proven by the detection of ). Since most HCPs exist in trace amounts and insufficient elution can result in concentrations below the detection limit of MS methods, this can be a particularly important issue when using only the F1-protein A fraction for proteomics research. Furthermore, PLBL2 levels in the protein A eluent (F3-protein A) depend on several parameters including mAb subclass (IgG4 has higher PLBL2 levels in the eluent than IgG1), PLBL2 concentration in the chromatographic loading solution, resin loading density, and pre-elution washing conditions.
[0175] A corresponding study was performed on the PLBL2 levels in fractions collected from FcγRIIIa chromatography. The measured principal signal intensity was observed in F1 (99.6%, MS signal: 5.6 x 10⁻⁶). 9This indicates that PLBL2 can be efficiently isolated using FcγRIIIa chromatography in a single step. Error! Reference source not found. Figures A and 7B show details of the PLBL2 signal intensity detected for protein A and FcγRIIIa chromatography, respectively.
[0176] Based on the results of the present invention, a novel FcγRIIIa-based approach for mAb depletion has been found to be more efficient than protein A chromatography. Most approved therapeutic mAbs are antibodies containing IgG1 or IgG4 constant regions, and these can be easily depleted using Fc receptor-based chromatography (e.g., FcγRIIIa chromatography) without significant optimization. Since HCP is isolated as a single fraction, the time required for sample preparation and data analysis is reduced. Consequently, process optimization is accelerated. The comprehensive information obtained using the workflow disclosed herein provides highly useful information regarding the identification of HCP in approved therapeutic mAbs to support the development of biosimilars.
[0177] List of references
[0178]
Claims
Claim 1 A method for isolating and analyzing one or more protein contaminants from a sample containing a recombinant protein and one or more protein contaminants, i. A method comprising: ii. a fractionation step of a sample comprising a recombinant protein and one or more protein contaminants, wherein the fractionation comprises contacting the sample with an Fc receptor affinity resin and collecting the pass-through to obtain a fraction comprising one or more protein contaminants; and ii. a step of analyzing one or more protein contaminants within the fraction comprising one or more protein contaminants. Claim 2 A method according to claim 1, wherein in step b) the analysis comprises the step of applying a fraction containing one or more protein contaminants to the concentration of one or more protein contaminants. Claim 3 In paragraph 2, the concentration of one or more protein contaminants is i. A method comprising: ii. a step of precipitating one or more protein contaminants; and ii. a step of dissolving one or more precipitated protein contaminants in a suitable solvent. Claim 4 A method according to any one of claims 1 to 3, wherein the analysis of step b) includes one or more fragmentation steps of protein contaminants. Claim 5 A method according to claim 4 comprising a chemical reduction step of one or more protein contaminants before or after fragmentation, preferably before fragmentation. Claim 6 A method according to any one of claims 1 to 5, wherein in step b) the analysis of one or more protein contaminants comprises a step of identifying one or more individual protein contaminants, preferably by peptide analysis by liquid chromatography-mass spectrometry (LC-MS). Claim 7 A method according to any one of claims 1 to 6, wherein the Fc receptor affinity resin comprises an immobilized Fc receptor that binds to a recombinant protein. Claim 8 A method according to any one of claims 1 to 7, wherein the Fc receptor affinity resin is an Fc gamma receptor affinity resin or a neonatal Fc receptor (FcRn) affinity resin, preferably an Fc gamma receptor affinity resin. Claim 9 A method according to claim 8, wherein the Fc gamma receptor affinity resin is a type I Fc gamma receptor (FcγR) affinity resin, a type II Fc gamma receptor (FcγR) affinity resin, or a type III Fc gamma receptor (FcγR) affinity resin; preferably, the Fc gamma receptor affinity resin is a type I Fc gamma receptor (FcγR) affinity resin; more preferably, the type I Fc gamma receptor (FcγR) affinity resin is selected from the group of FcγRI, FcγRIIa, FcγRIIb, FcγRIIc, FcγRIIIa, and FcγRIIIb affinity resins; and much more preferably, the type I Fc gamma receptor (FcγR) affinity resin is a FcγRIIIa affinity resin. Claim 10 A method of binding a recombinant protein to an Fc receptor affinity resin in any one of claims 1 to 9. Claim 11 A method according to any one of claims 1 to 10, wherein the recombinant protein comprises an Fc domain or a fragment of an Fc domain, preferably a glycosylated Fc domain or a fragment of a glycosylated Fc domain. Claim 12 A method according to any one of claims 1 to 11, wherein the recombinant protein is an antibody or its antigen-binding fragment or Fc fusion protein. Claim 13 A method according to any one of claims 1 to 12, wherein the recombinant protein comprises an IgG type invariant region; preferably, the IgG type invariant region is an IgG1 type invariant region, an IgG2 type invariant region, an IgG3 type invariant region, or an IgG4 type invariant region; more preferably, the IgG type invariant region is an IgG1 type invariant region, an IgG2 type invariant region, or an IgG4 type invariant region; and much more preferably, the IgG type invariant region is an IgG1 type invariant region or an IgG4 type invariant region. Claim 14 A method according to any one of claims 1 to 13, wherein the recombinant protein is an IgG-type antibody, preferably an IgG1-type antibody, an IgG2-type antibody, an IgG3-type antibody, or an IgG4-type antibody, more preferably an IgG1-type antibody, an IgG2-type antibody, or an IgG4-type antibody, and much more preferably an IgG1-type antibody or an IgG4-type antibody. Claim 15 A method according to any one of claims 1 to 14, wherein the recombinant protein is glycosylated, and preferably the recombinant protein comprises N-glycan. Claim 16 A method according to claim 15, wherein the N-glycan is an oligosaccharide having 3 to 20, preferably 3 to 15, particularly 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 sugar residues. Claim 17 In paragraph 3, the precipitation of one or more protein contaminants comprises a step of adding a precipitating agent; preferably, the precipitating agent is selected from the group consisting of trichloroacetic acid (TCA), acetone, ammonium sulfate, a combination of chloroform and methanol and water, and a combination of chloroform and methanol, and preferably acetone. Claim 18 A method according to claim 17, wherein the precipitation of one or more protein contaminants comprises the step of adding a precipitating agent in an amount of at least about 2:1 with respect to the volume of a fraction containing one or more protein contaminants; and the precipitation of one or more protein contaminants comprises the step of adding an aqueous salt solution; preferably, the step of adding the aqueous salt solution is performed before the addition of the precipitating agent; and more preferably, the aqueous salt solution is an aqueous solution of a salt selected from the group consisting of NaCl. Claim 19 A method according to any one of claims 3, 17, or 18, wherein the suitable solvent is an aqueous buffer containing a detergent, and preferably the detergent is selected from the group consisting of sodium deoxycholate, N-dodecyl-beta-D-maltoside, and combinations thereof. Claim 20 In claim 4, the fragmentation step of one or more protein contaminants is performed by protein hydrolytic digestion; preferably, the protein hydrolytic digestion includes a step of using a protease selected from the group consisting of trypsin, chymotrypsin, ArgC, GluC, AspN, LysC, LysN, elastase, proteinase K, and combinations thereof; more preferably, a method including a step of using trypsin and LysC. Claim 21 A method according to claim 4 or 20, wherein the protein hydrolytic digestion is performed at a temperature between about 34°C and about 40°C and / or; wherein the protein hydrolytic digestion comprises a step of using one or more protease(s) at a ratio between about 1:5 and 1:40 (w / w, protease(s) to protein substrate); and / or; wherein the protein hydrolytic digestion is allowed to proceed for at least about 15 minutes and / or; and wherein the protein hydrolytic digestion is allowed to proceed for about 30 minutes and about 60 minutes.
